Contact PD/PI: Murphy, Timothy F Buffalo Clinical and Translational Research Center The Buffalo Translational Consortium (BTC), which includes 12 major academic, research and healthcare institutions and 5 influential community partners in our region, have embarked on a comprehensive strategic plan to build a strong foundation for clinical and translational research in response to our community needs. Buffalo is the second most populous city in New York State and has a rich cultural history. The distribution of underrepresented minorities who experience health disparities in Buffalo in 2015 (50%) parallels that projected for the US in 2050, making Buffalo a microcosm of what the US will look like in 35 years. The vision for our CTSA hub is to develop, test and share novel approaches to improve health and reduce health disparities in our community, which represents a ?population of the future?. Improving health in our community and the nation will require innovative research across the full T1 through T4 translational spectrum. In 2012, the University at Buffalo opened the new 170,000 ft2 state-of-the-art Clinical and Translational Research Center (CTRC) devoted entirely to clinical and translational research. The CTRC provides a centralized facility, including translational research laboratories, a clinical research center, an imaging center, a lab animal facility and a biorepository. The CTRC and other enormous BTC investments to build a 21st century Academic Health Center creates a setting for a CTSA to provide the key piece to transform our capacity to bring discoveries in the laboratory, the clinic and the community to benefit individual and public health by sharing expertise and innovative approaches to translational science as part of the national consortium. We will bring strengths to the CTSA consortium, including developing novel health informatics tools, leveraging our strength as a leading center on research in standards and ontologies; new approaches to community-based research developed with our community; testing and disseminating ontology-based methods to share translational image data; and one of the few full service Drug Development Services in the consortium. With a CTSA we will 1) accelerate the development, implementation and dissemination of new healthcare interventions and their translation into the community through innovative research across the T1 through T4 spectrum, 2) train and develop an excellent and diverse workforce to ensure that translational researchers and their teams have the skills and knowledge to advance translation of discoveries, 3) build a translational science pipeline that integrates data from multiple sources and combines data analysis methods to discover diagnostic, therapeutic and preventive interventions, and 4) streamline clinical research processes with a focus on quality to enhance recruitment of special populations across the lifespan and groups with health disparities, and accelerate multi-site clinical trial initiation. Building on our unique strengths will enhance both our local and national CTSA network capacity through collaboration and sharing expertise and resources. Project Summary/Abstract Page 272 Contact PD/PI: Murphy, Timothy F Buffalo Clinical and Translational Research Center

Public Health Relevance

The Buffalo Clinical and Translational Research Center is the coordinating center of the Buffalo Translational Consortium which will perform innovative research across the T1 through T4 translational spectrum to improve health in our community and the nation. We have brought together the region's premier research, educational and clinical institutions with influential community partners to create a shared environment to bring discoveries in the laboratory, clinic and community to benefit individual and public health. Project Narrative Page 273

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
1UL1TR001412-01
Application #
9084932
Study Section
Special Emphasis Panel (ZTR1-SRC (99))
Program Officer
Chandler, Redonna
Project Start
2015-08-12
Project End
2019-03-31
Budget Start
2015-08-12
Budget End
2016-03-31
Support Year
1
Fiscal Year
2015
Total Cost
$3,161,454
Indirect Cost
$1,159,796
Name
State University of New York at Buffalo
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
038633251
City
Buffalo
State
NY
Country
United States
Zip Code
14260
Schweser, Ferdinand; Preda, Marilena; Zivadinov, Robert (2018) Susceptibility Weighted MRI in Rodents at 9.4 T. Methods Mol Biol 1718:205-234
Belov, P; Jakimovski, D; Krawiecki, J et al. (2018) Lower Arterial Cross-Sectional Area of Carotid and Vertebral Arteries and Higher Frequency of Secondary Neck Vessels Are Associated with Multiple Sclerosis. AJNR Am J Neuroradiol 39:123-130
Zivadinov, Robert; Polak, Paul; Schweser, Ferdinand et al. (2018) Multimodal Imaging of Retired Professional Contact Sport Athletes Does Not Provide Evidence of Structural and Functional Brain Damage. J Head Trauma Rehabil 33:E24-E32
Pasquariello, Kyle Z; Han, Marina; Unal, Cagla et al. (2018) Adrenergic manipulation inhibits pavlovian conditioned approach behaviors. Behav Brain Res 339:278-285
Bergsland, Niels; Schweser, Ferdinand; Dwyer, Michael G et al. (2018) Thalamic white matter in multiple sclerosis: A combined diffusion-tensor imaging and quantitative susceptibility mapping study. Hum Brain Mapp 39:4007-4017
Johnson, Blair D; O'Leary, Morgan C; McBryde, Muhamed et al. (2018) Face cooling exposes cardiac parasympathetic and sympathetic dysfunction in recently concussed college athletes. Physiol Rep 6:e13694
Ihnatovych, Ivanna; Lew, Alexandra; Lazar, Evelyn et al. (2018) Timing of Wnt Inhibition Modulates Directed Differentiation of Medial Ganglionic Eminence Progenitors from Human Pluripotent Stem Cells. Stem Cells Int 2018:3983090
Talal, Andrew H; Dumas, Emily O; Bauer, Barbara et al. (2018) Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage. J Infect Dis 217:474-482
Schweser, Ferdinand; Zivadinov, Robert (2018) Quantitative susceptibility mapping (QSM) with an extended physical model for MRI frequency contrast in the brain: a proof-of-concept of quantitative susceptibility and residual (QUASAR) mapping. NMR Biomed 31:e3999
Zhu, Xu; Shen, Xiaomeng; Qu, Jun et al. (2018) Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells. Front Pharmacol 9:84

Showing the most recent 10 out of 238 publications